Powis, Garth

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 697

Passing the baton: the HIF switch

Koh, M. Y., & Powis, G. (2012) · Trends in Biochemical Sciences

Cancer, Hypoxia, and MetabolismErythropoietin and Anemia Treatment

Cited by 589

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 532

The Absence of Mitochondrial Thioredoxin 2 Causes Massive Apoptosis, Exencephaly, and Early Embryonic Lethality in Homozygous Mice

Nonn, L., Williams, R. R., Erickson, R. P., & Powis, G. (2003) · Molecular and Cellular Biology

Redox biology and oxidative stressCell death mechanisms and regulation

Cited by 438

The Hypoxia-Associated Factor Switches Cells from HIF-1α- to HIF-2α-Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion

Koh, M. Y., Lemos, R., Liu, X., & Powis, G. (2011) · Cancer Research

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 350

HIF-1 regulation: not so easy come, easy go

Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2008) · Trends in Biochemical Sciences

Cancer, Hypoxia, and MetabolismErythropoietin and Anemia Treatment

Cited by 339

Hypoxia inducible factor-1α as a cancer drug target

Powis, G., & Kirkpatrick, L. (2004) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 311

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 309

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 290

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α

Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 240

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer

Spivak-Kroizman, T. R., Hostetter, G., Posner, R., Aziz, M., Hu, C., Demeure, M. J., Von Hoff, D., Hingorani, S. R., Palculict, T. B., Izzo, J., et al. (2013) · Cancer Research

Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway Studies

Cited by 202

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 123

HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer

Chang, H. R., Nam, S., Kook, M.-C., Kim, K.-T., Liu, X., Yao, H., Jung, H. R., Lemos, R., Seo, H. H., Park, H. S., et al. (2016) · Gut

Gastric Cancer Management and OutcomesMetabolism, Diabetes, and Cancer

Cited by 119

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma

Baker, A. F., Dragovich, T., Tate, W. R., Ramanathan, R. K., Roe, D., Hsu, C.-H., Kirkpatrick, D. L., & Powis, G. (2006) · Journal of Laboratory and Clinical Medicine

Redox biology and oxidative stressGlutathione Transferases and Polymorphisms

Cited by 90

Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice

Jacoby, J. J., Erez, B., Korshunova, M. V., Williams, R. R., Furutani, K., Takahashi, O., Kirkpatrick, L., Lippman, S. M., Powis, G., O'Reilly, M. S., et al. (2010) · Journal of Thoracic Oncology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 84

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase

Kim, Y. H., Coon, A., Baker, A. F., & Powis, G. (2011) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismRedox biology and oxidative stress

Cited by 45